Dublin, Calif. – September 16, 2021 – Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and genomic research, announces the Cielo 6, a real-time PCR instrument, has been validated for use with a new research-use only (RUO) assay to detect COVID-19 variants. In addition, the Cielo 3 and Cielo 6 are compatible with a family of kits for the diagnosis of a variety of diseases in human samples.
The PKAmp™ VariantDetect™ SARS-CoV-2 RT-PCR assay from PerkinElmer is a second-tier assay, designed to provide more information about a sample after a positive result from a first-tier diagnostic assay. The assay detects known variants and requires a qPCR instrument with fast cycling capability and the ability to detect multiple fluorescent labels. The Azure Cielo 6 meets these requirements with its capacity to multiplex up to six fluorescent channels per reaction.
View a full list of application notes using the Azure Cielo by clicking here.
The Viasure® Real Time PCR Detection Kits from CerTest Biotec are shelf-stable, ready-to-use plates containing all the components needed to carry out assays to detect a variety of human pathogens. Monoplex, multiplex, and panel assay kits are available for multiple target categories including gastrointestinal infections, tropical and vector-borne transmission diseases, and respiratory infections including SARS-CoV-2 variants, influenza, and RSV. The Azure Cielo 3 and 6 are low profile cyclers compatible with the VIASURE kits.
The Azure Cielo is an instrument engineered for increased sensitivity and reduced PCR run times compared to other RT-PCR instruments. Each LED is associated with 16 pairs of excitation and emission fibers to independently illuminate and detect 16 samples simultaneously, reducing plate movement and reducing light scatter associated with single illumination sources for excellent data consistency across different wells and different instruments.
For more information, contact info@azurebiosystems.com.
About Azure Biosystems
Azure Biosystems Inc. is an innovative life science platform company that designs, develops and markets state-of-the-art instruments, including the Cielo, and Azure Imaging Systems. By designing instruments that combine quantitative detection, enhanced flexibility, and streamlined workflows, we enable scientists to quickly and confidently advance their studies using the workflows that work best for them. With an experienced team that has decades of experience developing 2nd and 3rd generation imaging systems for the life science market, we create innovative platforms that set the definition of industry standards.
For additional information, please see https://www.azurebiosystems.com.
Contact
Lisa Isailovic, VP Marketing, Azure Biosystems
lisa.isailovic@azurebiosystems.com
(925) 307-7127
